{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:25:17Z","timestamp":1768548317689,"version":"3.49.0"},"posted":{"date-parts":[[2020,5,30]]},"group-title":"Cardiovascular Medicine","reference-count":25,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2020,7,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Interest exits concerning the use of angiotensin converting enzyme inhibitors (ACEi) in patients with Covid-19 disease.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To perform a systematic review on mortality associated to the use of ACEi in patients with Covid 19 disease.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Search in Medline (PubMed), in ISI Web of Knowledge and in medRxiv database; use of other sources.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 33 articles were evaluated. Concerning the papers used to produce the meta-analyses, seven studies were selected, five of which were used. These five studies involved a total number of 944 patients treated with ACEi and 5173 not treated with ACEi. Increased mortality was seen in association to the use of ACEi in the context of Covid-19 disease (ACEi users versus non-users; odds ratio, 1.48; 95% confidence interval [CI], 1.02 to 2.15; P=0.04). When compared to mortality in patients treated with angiotensin receptor blockers, mortality of patients treated with ACEi was not significantly different (odds ratio, 0.96; 95% confidence interval [CI], 0.76 to 1.21; P=0.74). Concerning the remaining reports, different types of data adjustments were used by several authors, after which increased mortality was not seen in association to the use of ACEi in this context.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ACEi use could act as a marker of increased mortality risk in some but not all Covid-19 disease settings. The data now presented do not prove a causal relation but argue in favor of carrying out clinical trials studying ACEi in Covid-19 patients, in order to establish the safety of ACEi use in this context.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2020.05.29.20116483","type":"posted-content","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T08:17:06Z","timestamp":1590826626000},"source":"Crossref","is-referenced-by-count":2,"title":["Mortality and use of angiotensin converting enzyme inhibitors in Covid 19 disease \u2013 a systematic review"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6739-0304","authenticated-orcid":false,"given":"Jos\u00e9 Pedro L.","family":"Nunes","sequence":"first","affiliation":[]}],"member":"54368","reference":[{"key":"2021010905400771000_2020.05.29.20116483v3.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.02.052"},{"key":"2021010905400771000_2020.05.29.20116483v3.2","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1111\/liv.13861","article-title":"Acute liver failure caused by hepatitis E virus genotype 3 and 4: A systematic review and pooled analysis","volume":"38","year":"2018","journal-title":"Liver Int"},{"key":"2021010905400771000_2020.05.29.20116483v3.3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","article-title":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","volume":"9","year":"2020","journal-title":"Emerging Microbes & Infections"},{"key":"2021010905400771000_2020.05.29.20116483v3.4","doi-asserted-by":"crossref","unstructured":"Jung S-Y , Choi JC , You S-H , Kim W-Y. Association of renin-angiotensin-aldosterone system inhibitors with COVID-19-related outcomes in Korea: a nationwide population-based cohort study. Clinical Infectious Diseases 2020.","DOI":"10.1093\/cid\/ciaa624"},{"key":"2021010905400771000_2020.05.29.20116483v3.5","unstructured":"Richardson S , Hirsch JS , Narasimhan M , et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020."},{"key":"2021010905400771000_2020.05.29.20116483v3.6","doi-asserted-by":"crossref","unstructured":"Giorgi Rossi P , Marino M , Formisano D , Venturelli F , Vicentini M , Grilli R. Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the Province of Reggio Emilia, Italy. medRxiv 2020:2020.04.13.20063545.","DOI":"10.1101\/2020.04.13.20063545"},{"key":"2021010905400771000_2020.05.29.20116483v3.7","doi-asserted-by":"crossref","unstructured":"Li J , Wang X , Chen J , Zhang H , Deng A. Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China. JAMA Cardiology 2020.","DOI":"10.1001\/jamacardio.2020.1624"},{"key":"2021010905400771000_2020.05.29.20116483v3.8","doi-asserted-by":"crossref","unstructured":"Felice C , Nardin C , Di Tanna GL , et al. Use of RAAS inhibitors and risk of clinical deterioration in COVID-19: results from an Italian cohort of 133 hypertensives. American Journal of Hypertension 2020.","DOI":"10.1093\/ajh\/hpaa096"},{"key":"2021010905400771000_2020.05.29.20116483v3.9","doi-asserted-by":"crossref","first-page":"e0235248","DOI":"10.1371\/journal.pone.0235248","article-title":"Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens","volume":"15","year":"2020","journal-title":"PLoS One"},{"key":"2021010905400771000_2020.05.29.20116483v3.10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0445OC"},{"key":"2021010905400771000_2020.05.29.20116483v3.11","doi-asserted-by":"crossref","first-page":"430","DOI":"10.21037\/atm.2020.03.229","article-title":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension","volume":"8","year":"2020","journal-title":"Ann Transl Med"},{"key":"2021010905400771000_2020.05.29.20116483v3.12","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","article-title":"Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19","volume":"126","year":"2020","journal-title":"Circ Res"},{"key":"2021010905400771000_2020.05.29.20116483v3.13","unstructured":"Zhou F , Liu Y-M , Xie J , et al. Comparative impacts of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on the risk of COVID-19 mortality. Hypertension;0."},{"key":"2021010905400771000_2020.05.29.20116483v3.14","doi-asserted-by":"crossref","unstructured":"Bean DM , Kraljevic Z , Searle T , et al. ACE-inhibitors and Angiotensin-2 Receptor Blockers are not associated with severe SARS-COVID19 infection in a multi-site UK acute Hospital Trust. Eur J Heart Fail 2020.","DOI":"10.1101\/2020.04.07.20056788"},{"key":"2021010905400771000_2020.05.29.20116483v3.15","doi-asserted-by":"crossref","unstructured":"Mancia G , Rea F , Ludergnani M , Apolone G , Corrao G. Renin\u2013Angiotensin\u2013Aldosterone System Blockers and the Risk of Covid-19. New England Journal of Medicine 2020.","DOI":"10.1056\/NEJMoa2006923"},{"key":"2021010905400771000_2020.05.29.20116483v3.16","doi-asserted-by":"crossref","unstructured":"Ip A , Parikh K , Parrillo JE , et al. Hypertension and Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. medRxiv 2020:2020.04.24.20077388.","DOI":"10.1101\/2020.04.24.20077388"},{"key":"2021010905400771000_2020.05.29.20116483v3.17","doi-asserted-by":"crossref","unstructured":"Reynolds HR , Adhikari S , Pulgarin C , et al. Renin\u2013Angiotensin\u2013Aldosterone System Inhibitors and Risk of Covid-19. New England Journal of Medicine 2020.","DOI":"10.1056\/NEJMoa2008975"},{"key":"2021010905400771000_2020.05.29.20116483v3.18","doi-asserted-by":"crossref","unstructured":"Khera R , Clark C , Lu Y , et al. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers with the Risk of Hospitalization and Death in Hypertensive Patients with Coronavirus Disease-19. medRxiv 2020:2020.05.17.20104943.","DOI":"10.1101\/2020.05.17.20104943"},{"key":"2021010905400771000_2020.05.29.20116483v3.19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy339"},{"key":"2021010905400771000_2020.05.29.20116483v3.20","doi-asserted-by":"crossref","unstructured":"Cummings MJ , Baldwin MR , Abrams D , et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet 2020.","DOI":"10.1016\/S0140-6736(20)31189-2"},{"key":"2021010905400771000_2020.05.29.20116483v3.21","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2018.0324"},{"key":"2021010905400771000_2020.05.29.20116483v3.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"2021010905400771000_2020.05.29.20116483v3.23","doi-asserted-by":"crossref","unstructured":"Jarcho JA , Ingelfinger JR , Hamel MB , D\u2019Agostino RB , Harrington DP . Inhibitors of the Renin\u2013Angiotensin\u2013Aldosterone System and Covid-19. New England Journal of Medicine 2020.","DOI":"10.1056\/NEJMe2012924"},{"key":"2021010905400771000_2020.05.29.20116483v3.24","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1097\/j.pbj.0000000000000035","article-title":"Medical therapeutics: mortality effects, uncertainty, and informed consent","volume":"4","year":"2019","journal-title":"Porto Biomedical Journal"},{"key":"2021010905400771000_2020.05.29.20116483v3.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1907805"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2020.05.29.20116483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:42:13Z","timestamp":1768484533000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2020.05.29.20116483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,30]]},"references-count":25,"URL":"https:\/\/doi.org\/10.1101\/2020.05.29.20116483","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1097\/j.pbj.0000000000000085","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2020,5,30]]},"subtype":"preprint"}}